<DOC>
	<DOC>NCT02305017</DOC>
	<brief_summary>Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more.</brief_summary>
	<brief_title>Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers</brief_title>
	<detailed_description>Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more. In one period, subjects received three single-doses of 1 g paracetamol separated by 6 hours and 1.5 hours after the last paracetamol dose a single-dose of 50 mg OPC was administered.In the other period, a single-dose of 50 mg OPC was administered alone.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subjects who are able and willing to give written informed consent. Male or female subjects aged between 18 and 45 years, inclusive. Subjects of body mass index (BMI) between 19.0 and 30.0 kg/m2, inclusive. Subjects who are healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead ECG. Subjects who have negative tests for HBsAg, antiHCVAb and HIV1 and HIV2 Ab at screening. Subjects who have clinical laboratory test results clinically acceptable at screening and admission to each treatment period. Subjects who have a negative screen for alcohol and drugs of abuse at screening and admission to each treatment period. Subjects who are nonsmokers or exsmokers for at least 3 months. (If female) She is not of childbearing potential by reason of surgery or, if of childbearing potential, she uses an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject) for all the duration of the study. (If female) She has a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 of each treatment period. Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. Subjects who have a clinically relevant surgical history. Subjects who have any clinically relevant abnormality in the coagulation tests. Subjects who have any clinically relevant abnormality in the liver function tests (a casebycase decision for any abnormality must be discussed with the Sponsor before inclusion). Subjects who have a history of relevant atopy or drug hypersensitivity, particularly to paracetamol or any COMT inhibitor. Subjects who have a history of alcoholism or drug abuse. Subjects who consume more than 14 units of alcohol a week. Subjects who have a significant infection or known inflammatory process at screening or admission to each treatment period. Subjects who have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period. Subjects who have received paracetamol within 2 weeks of admission to the first period. Subjects who have used any other medicines within 2 weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion. Subjects who have previously received OPC. Subjects who have used any investigational drug or participated in any clinical trial within 90 days prior to screening. Subjects who have participated in more than 2 clinical trials within the 12 months prior to screening. Subjects who have donated or received any blood or blood products within the 3 months prior to screening. Subjects who are vegetarians, vegans or have medical dietary restrictions. Subjects who cannot communicate reliably with the investigator. Subjects who are unlikely to cooperate with the requirements of the study. Subjects who are unwilling or unable to give written informed consent. (If female) She is pregnant or breastfeeding. (If female) She is of childbearing potential and she does not use an approved effective contraceptive method or she uses oral contraceptives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>